Skip to main content
CDNACareDx, Inc.Sell6.4·$49.86+6.12%

CareDx (CDNA) Q2 2026 earnings — TrendMatrix coverage

BEAT+59.5% vs estimateEPS $0.37 vs $0.23 estVerdict Buy (Wait)Hold

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure

Event detail · Q2 2026

Key numbers

Reported EPS
$0.37
Estimate
$0.23
Surprise
+59.5%
Revenue (period 2026-06-30)
$131.9M
Score at report (before → after)
6.05.9/10

Revenue source: xbrl.

Report record · Q2 2026

How the report landed

CareDx (CDNA) beat the $0.23 estimate with diluted EPS of $0.37 — a large 59.5% upside surprise. TrendMatrix's engine moved from Buy (Wait) (6.0/10) to Hold at 5.9/10 after the report — the engine's score fell despite the beat.

Current read · as of 2026-08-23

Where TrendMatrix's rating stands now

TrendMatrix currently rates CDNA Sell at 6.4/10.

3 of the last 4 quarters beat the estimate; this quarter's +59.5% surprise compares with a +67.9% four-quarter average. Next scheduled report: 2026-11-03.

What supports the rating

  • Strong earnings beat streak (3/4)
  • High-quality business

What argues against it

  • Concentration risk — Product: AlloSure/AlloMap/HeartCare transplant tests
  • Analyst target reached - limited upside remaining
  • Near 52-week high (2.3% away)

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current engine read

The levels TrendMatrix's engine tracks

Current price
$49.86
Price target
$55.90
Stop
$45.21
Upside to target
+12.1%

Forward estimates sit below the trailing run-rate (35.9× forward vs 22.6× trailing) — consensus expects earnings to decline from here.

Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.

Healthcare context

CDNA at TrendMatrix's latest read

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry
Diagnostics & Research
Market cap
$2.51B
P/E (fwd)
35.9
P/E (ttm)
22.6
52-week range
$12.37$49.76
Off 52-week high
-0.2%
RSI (14)
53
Volume vs avg
0.97×
Score today
6.4/10

Earnings figures are sourced from TrendMatrix’s pipeline (EPS: existing earnings extraction; revenue: SEC XBRL company facts where available, yfinance-provisional otherwise). Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home Stocks CDNA Earnings Q2 2026 earnings